Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02186 LUYE PHARMA
RTNominal up3.110 +0.030 (+0.974%)
Others

30/12/2021 11:46

Luye Pharma (02186) gets application accepted

[ET Net News Agency, 30 December 2021] Luye Pharma Group Ltd. (02186) said the
marketing authorization application for the group's innovative formulation product
Goserelin Acetate Extended-release Microspheres for Injection (LY01005) has been accepted
by the Centre for Drug Evaluation of the National Medical Products Administration (NMPA)
in the People's Republic of China.
The indication submitted for this marketing authorization application in China is
prostate cancer. Concurrently with this application, the group is also undertaking phase
III clinical trials for LY01005 for treatment of breast cancer in China. (RC)

Back to Others

Remark: Real time quote last updated: 25/09/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.